Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention

Pharmacol Rep. 2021 Dec;73(6):1539-1550. doi: 10.1007/s43440-021-00303-6. Epub 2021 Jun 27.

Abstract

Angiotensin-converting enzyme (ACE) and its homologue, ACE2, are commonly allied with hypertension, renin-angiotensin-aldosterone system pathway, and other cardiovascular system disorders. The recent pandemic of COVID-19 has attracted the attention of numerous researchers on ACE2 receptors, where the causative viral particle, SARS-CoV-2, is established to exploit these receptors for permitting their entry into the human cells. Therefore, studies on the molecular origin and pathophysiology of the cell response in correlation to the role of ACE2 receptors to these viruses are bringing novel theories. The varying level of manifestation and importance of ACE proteins, underlying irregularities and disorders, intake of specific medications, and persistence of assured genomic variants at the ACE genes are potential questions raising nowadays while observing the marked alteration in response to the SARS-CoV-2-infected patients. Therefore, the present review has focused on several raised opinions associated with the role of the ACE2 receptor and its impact on COVID-19 pathogenesis.

Keywords: Acute lung injury; Acute respiratory distress syndrome; Angiotensin-converting enzyme-2; COVID-19; SARS-CoV-2; rhACE2.

Publication types

  • Review

MeSH terms

  • Acute Lung Injury
  • Angiotensin-Converting Enzyme 2 / deficiency
  • Angiotensin-Converting Enzyme 2 / metabolism*
  • Angiotensin-Converting Enzyme 2 / pharmacology*
  • Angiotensin-Converting Enzyme 2 / therapeutic use
  • COVID-19 Drug Treatment*
  • Humans
  • Hypertension / drug therapy
  • SARS-CoV-2 / pathogenicity*
  • Spike Glycoprotein, Coronavirus / metabolism

Substances

  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2